SCHEMBL19643597

SCHEMBL19643597

COC(=O)c1ccnc2cc(OS(=O)(=O)C(F)(F)F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
KDR P35968 3/20 0.42
CLK2 P49760 2/20 0.42
HIPK4 Q8NE63 2/20 0.42
SRPK1 Q96SB4 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
STK17A Q9UEE5 2/20 0.42
IRAK1 P51617 1/20 0.42
NEK4 P51957 1/20 0.42
MAP4K2 Q12851 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
MAP3K20 Q9NYL2 1/20 0.42
MAP4K5 Q9Y4K4 1/20 0.42
SLC40A1 Q9NP59 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
PLK4 O00444 1/20 0.40
DYRK3 O43781 1/20 0.40
MAP4K4 O95819 1/20 0.40
CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747240 0.82 LMNA (0.58) LMNAKDRCLK2HIPK4SRPK1
SCHEMBL25386462 0.79 LMNA (0.46) LMNAKDRKDM4EPSMD14HTR1A
SCHEMBL19644053 0.78 CFTR (0.54) KDRCLK2HIPK4SRPK1CLK4
SCHEMBL272962 0.78 PDE4B (0.51) LMNAKDRAURKBCXCR2HSD11B1
SCHEMBL5569165 0.77 HSD11B1 (0.47) LMNACXCR2HSD11B1KDM4ECA1
SCHEMBL26965996 0.77 CFTR (0.43) LMNAKDRCLK2HIPK4SRPK1
SCHEMBL19957320 0.77 CA1 (0.41) KDRCLK2HIPK4SRPK1CLK4
SCHEMBL31153486 0.76 GAK (0.47) LMNAKDRCLK4ACVR1KDM4E
SCHEMBL3551410 0.76 HTR1A (0.46) LMNAKDRCLK2HIPK4SRPK1
SCHEMBL2114719 0.75 MTNR1A (0.50) HSD11B1PLA2G2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190202811-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2019-07-04 US disclosed
US-20190202811-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2019-07-04 US disclosed
EP-3463341-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES The Rockefeller University (US) 2019-04-10 EP disclosed
WO-2017205296-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2017-11-30 WO disclosed
WO-2017205296-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202811-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI2, IL4I1, TFPI LMNA 3993/4885KDR 4397/4885CLK2 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.